Delcath Systems Inc (DCTH)

Currency in USD
8.900
-0.100(-1.11%)
Closed·
8.890-0.010(-0.11%)
·
DCTH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.4859.109
52 wk Range
8.12018.230
Key Statistics
Prev. Close
9
Open
9.01
Day's Range
8.485-9.109
52 wk Range
8.12-18.23
Volume
946.66K
Average Volume (3m)
505.44K
1-Year Change
-37.1912%
Book Value / Share
3.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DCTH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.333
Upside
+139.70%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Delcath Systems Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Delcath Systems Inc Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Delcath Systems Inc Earnings Call Summary for Q4/2025

  • Q4 2025 revenue hit $20.73M, beating forecast by 3.19%; EPS of -$0.05 surpassed expected -$0.08 by 37.5%, though stock fell 6.46% in pre-market.
  • Annual revenue reached record $85.2M in 2025; company achieved net income of $2.7M, reversing prior year's $26.4M loss with 85% gross margin.
  • HEPZATO KIT sales surged 144% year-over-year, driving growth as company scales operations and expands product portfolio across treatment centers.
  • Management projects Q1 2026 revenue of $23.5M and Q2 2026 revenue of $25.7M with EPS improving to $0.04 in Q2, signaling continued profitability trajectory.
  • Key risks include potential market saturation, regulatory delays in treatment expansion, and revenue concentration in limited products amid seasonal demand patterns.
Last Updated: 02/26/2026, 10:46 PM
Read Full Transcript

Compare DCTH to Peers and Sector

Metrics to compare
DCTH
Peers
Sector
Relationship
P/E Ratio
114.4x−6.6x−0.6x
PEG Ratio
1.06−0.180.00
Price/Book
2.8x4.3x2.6x
Price / LTM Sales
3.6x3.8x3.3x
Upside (Analyst Target)
124.7%45.5%44.8%
Fair Value Upside
Unlock9.0%5.5%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 21.333
(+139.70% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Craig-Hallum
Buy18.00+102.25%20.00MaintainFeb 27, 2026
Clear Street
Buy27.00+203.37%29.00MaintainFeb 26, 2026
BTIG
Buy19.00+113.48%23.00MaintainFeb 26, 2026
Stephens
Buy18.00+102.25%25.00MaintainNov 05, 2025
Craig-Hallum
Buy20.00+124.72%24.00MaintainOct 21, 2025

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
-0.05 / -0.08
Revenue / Forecast
20.73M / 20.09M
EPS Revisions
Last 90 days

DCTH Income Statement

People Also Watch

10.080
ONDS
-3.54%
9.070
RDW
-5.03%
40.950
IREN
-7.44%
11.190
PGY
-9.83%
5.6950
EOSE
-15.50%

FAQ

What Is the Delcath Systems (DCTH) Stock Price Today?

The Delcath Systems stock price today is 8.900 USD.

What Stock Exchange Does Delcath Systems Trade On?

Delcath Systems is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Delcath Systems?

The stock symbol for Delcath Systems is "DCTH."

What Is the Delcath Systems Market Cap?

As of today, Delcath Systems market cap is 308.830M USD.

What Is Delcath Systems's Earnings Per Share (TTM)?

The Delcath Systems EPS (TTM) is 0.075.

When Is the Next Delcath Systems Earnings Date?

Delcath Systems will release its next earnings report on May 12, 2026.

From a Technical Analysis Perspective, Is DCTH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Delcath Systems Stock Split?

Delcath Systems has split 5 times.

How Many Employees Does Delcath Systems Have?

Delcath Systems has 96 employees.

What is the current trading status of Delcath Systems (DCTH)?

As of Feb 28, 2026, Delcath Systems (DCTH) is trading at a price of 8.900 USD, with a previous close of 9.000 USD. The stock has fluctuated within a day range of 8.485 USD to 9.109 USD, while its 52-week range spans from 8.120 USD to 18.230 USD.

What Is Delcath Systems (DCTH) Price Target According to Analysts?

The average 12-month price target for Delcath Systems is 21.333 USD, with a high estimate of 30 USD and a low estimate of 18 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +139.70% Upside potential.

What Is the DCTH Premarket Price?

DCTH's last pre-market stock price is 9.050 USD. The pre-market share volume is 220.000, and the stock has decreased by 0.050, or 0.560%.

What Is the DCTH After Hours Price?

DCTH's last after hours stock price is 8.890 USD, the stock has decreased by -0.010, or -0.110%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.